Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Blue Oak, PsychoGenics Partner for Drug Discovery | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Blue Oak, PsychoGenics Partner for Drug Discovery

The partnership is focused on the discovery of treatments for various psychiatric conditions

By: Betsy Louda

, Contract Pharma

Blue Oak Pharmaceuticals and PsychoGenics have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions. 

 

Under the terms of the agreement, PsychoGenics is providing access to its phenotypic discovery platforms, including its SmartCube system and machine learning expertise, for unbiased discovery of novel therapeutics for brain disorders identified from the Blue Oak library of privileged chemotypes. The PsychoGenics technology platforms combine broad in vivo behavioral expertise with developments in robotics, computer vision, and bioinformatics to evaluate drug candidates for potential utility across the spectrum of CNS disease indications. 

 

“We have a strong, 10-year relationship with Dr. Emer Leahy and PsychoGenics that has validated our systems neurobiology paradigm for discovering clinical molecules with mechanisms-of-action distinct from existing drugs. We are confident that combining PGI’s deep behavioral profiling with Blue Oak’s privileged chemotypes and brain imaging biomarkers will yield the new therapies that have eluded the industry for several decades” said Tom Large, Ph.D., Blue Oak’s president and chief executive officer. 

 

PsychoGenics’ prior work includes an investigational psychotropic agent that is being studied in Phase II clinical trials as a treatment for patients with schizophrenia and for Parkinson’s disease psychosis. 

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics